Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Type
Public
HQ
Chandler, US
Founded
1998
Size (employees)
510 (est)
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US

Key People at Insys Therapeutics

Michael L. Babich

Michael L. Babich

CEO
Darryl S. Baker

Darryl S. Baker

CFO
Larry Dillaha

Larry Dillaha

CMO

Insys Therapeutics Office Locations

Insys Therapeutics has office in Chandler
Chandler, US

Insys Therapeutics Metrics

Insys Therapeutics Summary

Market capitalization

$919 M

Closing share price

$13.5
Insys Therapeutics's current market capitalization is $919 M.

Insys Therapeutics Financials

Insys Therapeutics's revenue is $331 M in FY, 2015 which is 48.92% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$331 M$222 M$99.3 M

Revenue growth, %

48.9%123.7%

Gross profit

$302 M$200 M$86.6 M

Operating income

$92.4 M$64 M$32.6 M

Operating expense total

$210 M$136 M$54.1 M

Net Income

$58.5 M$38 M$40.4 M

Operating cash flow

$21.4 M$12.7 M$45 M

Insys Therapeutics Market Value History

Insys Therapeutics News

Insys Therapeutics Company Life

You may also be interested in